213 related articles for article (PubMed ID: 35839615)
1. Treatment outcomes of first-ever episode of severe optic neuritis.
Galetta K; Ryan S; Manzano G; Chibnik LB; Balaban D; Prasad S; Chwalisz BK; Salazar-Camelo A; Conway S; Levy M; Matiello M
Mult Scler Relat Disord; 2022 Oct; 66():104020. PubMed ID: 35839615
[TBL] [Abstract][Full Text] [Related]
2. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks.
Chen JJ; Flanagan EP; Pittock SJ; Stern NC; Tisavipat N; Bhatti MT; Chodnicki KD; Tajfirouz DA; Jamali S; Kunchok A; Eggenberger ER; Nome MAD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Moss HE; Navarro SEV; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Danesh-Meyer H; Ivanov S; Huda S; Forcadela M; Hodge D; Poullin P; Rode J; Papeix C; Saheb S; Boudot de la Motte M; Vignal C; Hacohen Y; Pique J; Maillart E; Deschamps R; Audoin B; Marignier R
Am J Ophthalmol; 2023 Aug; 252():213-224. PubMed ID: 36822570
[TBL] [Abstract][Full Text] [Related]
3. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
[TBL] [Abstract][Full Text] [Related]
4. Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein.
Ducloyer JB; Michel L; Wiertlewski S; Lebranchu P
Eur J Ophthalmol; 2019 Mar; 29(2):257-261. PubMed ID: 29972029
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica.
Ambika S; Durgapriyadarshini S; Padmalakshmi K; Noronha V; Arjundas D
Indian J Ophthalmol; 2022 Jan; 70(1):194-200. PubMed ID: 34937238
[TBL] [Abstract][Full Text] [Related]
6. Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
Masuda H; Mori M; Yokouchi H; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Yamamoto S; Kuwabara S
J Neurol; 2022 Apr; 269(4):1996-2003. PubMed ID: 34455476
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
[TBL] [Abstract][Full Text] [Related]
8. Optic neuritis in Turkish children and adolescents: A multicenter retrospective study.
Direk MÇ; Besen Ş; Öncel İ; Günbey C; Özdoğan O; Orgun LT; Sahin S; Cansu A; Yıldız N; Kanmaz S; Yılmaz S; Tekgül H; Türkdoğan D; Ünver O; Thomas GÖ; Başıbüyük S; Yılmaz D; Kurt AN; Gültutan P; Özsoy Ö; Yiş U; Kurul SH; Güngör S; Özgör B; Karadağ M; Dündar NO; Gençpınar P; Bildik O; Orak SA; Kabur ÇÇ; Kara B; Karaca Ö; Canpolat M; Gümüş H; Per H; Yılmaz Ü; Karaoğlu P; Ersoy Ö; Tosun A; Öztürk SB; Yüksel D; Atasoy E; Gücüyener K; Yıldırım M; Bektaş Ö; Çavuşoğlu D; Yarar Ç; Güngör O; Mert GG; Sarıgeçili E; Edizer S; Çetin İD; Aydın S; Diler B; Özdemir AA; Erol İ; Okuyaz Ç; Anlar B
Mult Scler Relat Disord; 2024 Jan; 81():105149. PubMed ID: 38096730
[TBL] [Abstract][Full Text] [Related]
9. The Treatment of Acute Optic Neuritis.
Keyhanian K; Chwalisz BK
Semin Ophthalmol; 2023 Aug; 38(6):511-514. PubMed ID: 37162276
[TBL] [Abstract][Full Text] [Related]
10. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
[TBL] [Abstract][Full Text] [Related]
11. [Optic neuropathy in positive anti-MOG antibody syndrome].
Merabtene L; Vignal Clermont C; Deschamps R
J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
[TBL] [Abstract][Full Text] [Related]
12. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
13. Plasma exchange response in 34 patients with severe optic neuritis.
Deschamps R; Gueguen A; Parquet N; Saheb S; Driss F; Mesnil M; Vignal C; Aboab J; Depaz R; Gout O
J Neurol; 2016 May; 263(5):883-887. PubMed ID: 26964539
[TBL] [Abstract][Full Text] [Related]
14. Poor Visual Outcome After First Attack in a Cohort of Patients With Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis.
Handzic A; Naidu S; Brossard-Barbosa N; Margolin E
J Neuroophthalmol; 2024 Jun; 44(2):178-183. PubMed ID: 37824275
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Mult Scler Relat Disord; 2023 Apr; 72():104611. PubMed ID: 36907119
[TBL] [Abstract][Full Text] [Related]
16. An update on optic neuritis.
Kraker JA; Chen JJ
J Neurol; 2023 Oct; 270(10):5113-5126. PubMed ID: 37542657
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
18. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
19. [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment].
Wildemann B; Horstmann S; Korporal-Kuhnke M; Viehöver A; Jarius S
Klin Monbl Augenheilkd; 2020 Nov; 237(11):1290-1305. PubMed ID: 33202462
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
